Exact Sciences has appointed Mark Stenhouse to the new role of president for its flagship product Cologuard, a non-invasive stool-based DNA test for early detection of colorectal cancer. Stenhouse, who is currently serving as vice president of the US immunology group at AbbVie, will assume this new position on April 2. At AbbVie, Stenhouse leads the sales and marketing teams for the anti-inflammatory drug Humira. He has spent nearly 30 years at Abbott Laboratories/AbbVie, where he was first hired for a field sales position. He became national sales director in the US immunology-gastroenterology franchise, and rose to marketing director, followed by senior director of commercial initiatives. In 2010, Stenhouse was appointed a general manager within the company before being promoted to vice president.